Corcept Therapeutics Inc (CORT)
50.07
+2.45
(+5.14%)
USD |
NASDAQ |
Nov 04, 16:00
50.07
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Gross Profit Margin (Quarterly): 98.43% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 98.43% |
| June 30, 2024 | 98.46% |
| March 31, 2024 | 98.27% |
| December 31, 2023 | 98.61% |
| September 30, 2023 | 98.67% |
| June 30, 2023 | 98.66% |
| March 31, 2023 | 98.69% |
| December 31, 2022 | 98.56% |
| September 30, 2022 | 98.68% |
| June 30, 2022 | 98.73% |
| March 31, 2022 | 98.67% |
| December 31, 2021 | 98.63% |
| September 30, 2021 | 98.67% |
| June 30, 2021 | 98.49% |
| March 31, 2021 | 98.40% |
| December 31, 2020 | 98.54% |
| September 30, 2020 | 98.59% |
| June 30, 2020 | 98.61% |
| March 31, 2020 | 97.99% |
| December 31, 2019 | 98.37% |
| September 30, 2019 | 98.22% |
| June 30, 2019 | 98.09% |
| March 31, 2019 | 98.09% |
| December 31, 2018 | 97.64% |
| September 30, 2018 | 97.97% |
| Date | Value |
|---|---|
| June 30, 2018 | 98.15% |
| March 31, 2018 | 97.96% |
| December 31, 2017 | 97.83% |
| September 30, 2017 | 97.72% |
| June 30, 2017 | 97.82% |
| March 31, 2017 | 97.66% |
| December 31, 2016 | 97.64% |
| September 30, 2016 | 96.93% |
| June 30, 2016 | 97.84% |
| March 31, 2016 | 97.49% |
| December 31, 2015 | 97.57% |
| September 30, 2015 | 98.07% |
| June 30, 2015 | 96.33% |
| March 31, 2015 | 97.01% |
| December 31, 2014 | 97.14% |
| September 30, 2014 | 96.77% |
| June 30, 2014 | 96.33% |
| March 31, 2014 | 96.05% |
| December 31, 2013 | 98.52% |
| September 30, 2013 | 98.48% |
| June 30, 2013 | 98.78% |
| March 31, 2013 | 98.84% |
| December 31, 2012 | 98.62% |
| September 30, 2012 | 97.73% |
| June 30, 2012 | 94.51% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
97.99%
Minimum
Mar 2020
98.73%
Maximum
Jun 2022
98.54%
Average
98.60%
Median
Gross Profit Margin (Quarterly) Benchmarks
| ADMA Biologics Inc | 53.60% |
| Akebia Therapeutics Inc | 60.94% |
| Bioventus Inc | 68.54% |
| Alnylam Pharmaceuticals Inc | 82.85% |
| Catalyst Pharmaceuticals Inc | 87.45% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 25.77% |
| Return on Assets | 21.04% |
| Return on Invested Capital | 25.77% |
| Profit Margin (Quarterly) | 25.86% |
| Operating Margin (Quarterly) | 25.53% |
| Return on Net Operating Assets | 199.0% |